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Streptococcus pneumoniae is a frequent member of the microbiota of the human 30 
nasopharynx. Colonization of the nasopharyngeal tract is a first and necessary step 31 
in the infectious process and often involves the formation of sessile microbial 32 
communities by this human pathogen. The ability to grow and persist as biofilms is 33 
an advantage for many microorganisms because biofilm-grown bacteria show a 34 
reduced susceptibility to antimicrobial agents and hinder the recognition by the 35 
immune system. Host protection against biofilm-related pneumococcal disease has 36 
not been defined yet. Using pneumococcal strains growing as planktonic cultures 37 
or as biofilms, we have investigated the recognition of S. pneumoniae by the 38 
complement system and its interactions with human neutrophils. Deposition of 39 
C3b, the key complement component, was impaired on S. pneumoniae biofilms. In 40 
addition, binding of C-reactive protein and the complement component C1q to the 41 
pneumococcal surface was reduced in biofilm-growing bacteria demonstrating that 42 
pneumococcal biofilms avoid the activation of the classical complement pathway. 43 
Besides, recruitment of factor H, the down-regulator of the alternative pathway 44 
was enhanced by S. pneumoniae growing as biofilms. Our results also show that 45 
biofilm formation diverts the alternative complement pathway activation by a 46 
PspC-mediated mechanism. Furthermore, phagocytosis of pneumococcal biofilms 47 
was also impaired. The present study confirms that biofilm formation in S. 48 
pneumoniae is an efficient way for host immune evasion both from the classical 49 




treptococcus pneumoniae, the pneumococcus, is the leading pathogen producing 52 
acute otitis media, community-acquired pneumonia, and invasive diseases 53 
including bacterial meningitis and sepsis (1). The growth and dispersal of microbes, 54 
whether pathogenic or environmental, commonly involve the production of biofilms, 55 
which represent the primary mode of pneumococcal growth during colonization, 56 
recurrent otitis media and the early stages of invasive disease (2-4). These evidences 57 
support the importance of studying pneumococcal sessile communities to understand 58 
key events in the pathogenesis development of this important human pathogen.  59 
Biofilm formation is a complex process initiated by the attachment of 60 
microorganisms to a surface or interface that is embedded in an extracellular matrix 61 
constituted by various polymeric substances (5, 6). The biological and physicochemical 62 
characteristics of biofilm structure protect the bacterium from environmental adversities 63 
and confer the microorganism an inherent resistance to antimicrobial therapies and the 64 
host immune response (6, 7). It is well known that the complement system represents 65 
one of the first lines of defense against invading pathogens such as S. pneumoniae and 66 
plays a vital role in both innate and acquired immunity (8). This unique host defense 67 
mechanism is activated by three different pathways —known as the classical, alternative 68 
and lectin pathways— that converge at the central component C3, which is involved in 69 
essential phases of the immune response such as recognition and clearance of 70 
microorganisms, inflammatory response and induction of phagocytosis (8, 9). The 71 
classical complement pathway is activated by the recognition of antigen-antibody 72 
complexes on the bacterial surface by the complement component C1q and it is 73 
generally considered to be an effector of the acquired immune response. This cascade 74 
plays a vital role for complement activation against pneumococci (10, 11). However, the 75 
classical pathway has also an important role as part of the innate immune response to S. 76 
pneumoniae since it is activated by other innate immune mediators such as the natural 77 
IgM, the C-reactive protein (CRP), the serum amyloid P protein (SAP), or the lectin 78 
receptor SIGN-R1 (10-12). Besides, the alternative pathway is activated by the 79 




deposition and, therefore, contributes significantly to innate immunity (13). In addition, 81 
an MBL-independent lectin pathway activation has been recently demonstrated, 82 
confirming the importance of complement-mediated immunity against S. pneumoniae 83 
(14). 84 
Although avoidance of complement immunity and phagocytosis is a clear advantage 85 
for bacterial dissemination it may also be a common immune evasion strategy used by 86 
selected pathogens to allow long-term colonization and persistent carriage. In this sense, 87 
there are several studies reporting the importance of biofilm formation by various 88 
microorganisms in the evasion of the host immune response (15-17), although the 89 
interactions of pneumococcal biofilms with complement immunity and phagocytic cells 90 
is largely unknown.  91 
In this study, we have investigated the recognition by the complement system and 92 
human neutrophils of S. pneumoniae growing either as biofilms or planktonic cultures 93 
by exploring how acute phase proteins and complement down-regulators interact with 94 
these two different bacterial life styles.  95 
MATERIALS AND METHODS 96 
Bacterial strains and growth conditions. S. pneumoniae non-encapsulated strains used 97 
for this study were: strain R6 (a D39 derivative) (18), strain P040 expressing the green 98 
fluorescent protein (GFP) [R6 (pMV158GFP) obtained by transformation with plasmid 99 
DNA; tetracycline resistant], strain P064 [R6 but pspC::aad9 constructed by mariner 100 
mutagenesis, displaying anti-transcribed orientation of the antibiotic resistance cassette 101 
of the minitransposon with respect to the targeted gene; spectinomycin-resistant] (19). 102 
An encapsulated pneumococcal clinical isolate of serotype 19A (strain 1041) from a 103 
patient with sepsis was used. Bacterial strains were grown at 37°C in C medium (20) 104 
containing 33 mM potassium phosphate buffer at pH 8.0 (CpH8 medium) either 105 
supplemented (or not) with 0.8 mg ml–1 yeast extract (C+Y medium). Biofilm formation 106 
by pneumococcal cells was obtained using 96-well polystyrene microtiter plates (Costar 107 
3595; Corning) as previously described (19, 21). Briefly, cells were grown in C+Y 108 
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medium to an optical density of 0.5–0.6 at 550 nm (OD550), sedimented by 109 
centrifugation, resuspended in an equal volume of CpH8 medium, diluted 1/100, and 110 
then 200 μl containing 5 × 106 CFU ml–1 were dispensed in 96 well plates for biofilm 111 
formation or in sterile Falcon tubes for planktonic replication growth. Both cultures 112 
were incubated during 5 h at 34°C.  113 
Complement factors binding to S. pneumoniae strains. Human serum from five 114 
healthy male volunteers unvaccinated against S. pneumoniae (median age of 40 years) 115 
were obtained with informed consent according to institutional guidelines and stored as 116 
single-use aliquots at −70°C as a source of complement and serum components. C1q, 117 
C3b, factor H (FH), C4b-binding protein (C4BP) and CRP were assessed using flow 118 
cytometry assays as previously described (11). After the incubation process at 34°C, 119 
bacterial cultures growing as biofilms in microtiter plates or in the planktonic form were 120 
washed with fresh CpH8 medium and resuspended in phosphate-buffered saline (pH 121 
7.0) (PBS). Biofilm disaggregation was performed by gently pipetting and slow 122 
vortexing before the opsonization process to avoid possible bias by morphological 123 
differences between the two growing stages. The corresponding bacterial suspensions 124 
(20 μl) were added to tubes containing 20 μl of human serum diluted 1/5 in PBS and 125 
samples were incubated during 20 min at 37°C to allow opsonization by the different 126 
serum components. Previously, the number of biofilm-forming CFU was determined by 127 
viable counts of bacteria and a similar number of planktonic cells were used in each 128 
assay.  129 
C1q and C3b deposition were detected by incubating the bacteria with 50 μl of a 130 
fluorescein isothiocyanate- (FITC-) conjugated polyclonal sheep anti-human C1q 131 
antibody (Serotec) or a FITC-conjugated polyclonal goat anti-human C3b antibody 132 
(ICN-Cappel) diluted 1/300 or 1/500 in PBS/0.1% Tween 20 respectively. Bacterial 133 
suspensions and antibodies were incubated during 2 h at 37°C for C1q detection or 134 
during 30 min on ice for C3b analysis. The deposition of CRP, FH and C4BP was 135 
investigated by using a polyclonal rabbit anti-human CRP antibody (Calbiochem), a 136 
polyclonal sheep anti-human FH antibody (Serotec) and a polyclonal sheep anti-human 137 
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C4BP antibody (Serotec) for 1 h at 37°C respectively followed by a secondary staining 138 
in PBS/0.1% Tween 20 containing FITC-conjugated polyclonal goat anti-rabbit, or 139 
FITC/DYLIGHT 649 donkey anti-sheep antibodies (Serotec). After incubations, the 140 
bacteria were washed with PBS/0.1% Tween 20 to remove unbound components, fixed 141 
in 3% paraformaldehyde and analyzed on a FACS Calibur flow cytometer (BD 142 
Biosciences) using forward and side scatter parameters to gate on at least 25,000 143 
bacteria. The results were expressed as a relative % fluorescence index (FI) that 144 
measures not only the proportion of fluorescent bacteria positive for the host serum 145 
component investigated but also the intensity of fluorescence that quantify the immune 146 
component bound (11, 22).  147 
C3b analysis by confocal laser scanning microscopy. To determine C3b deposition 148 
on S. pneumoniae, the R6 strain was first grown as biofilm and planktonic culture as 149 
described above using glass-bottom dishes (WillCo-dish; WillCo Wells B. V., The 150 
Netherlands) or sterile Falcon tubes, respectively. Pneumococcal biofilm and planktonic 151 
culture samples were incubated with human serum as a source of complement and the 152 
different samples were incubated during 20 min at 37°C to allow opsonization by the 153 
C3b component. A FITC-conjugated polyclonal goat anti-human C3b antibody (ICN-154 
Cappel) was used to detect the C3b bound using a Leica TCS-SP5-AOBS-UV confocal 155 
laser scanning microscope (CLSM) equipped with an argon ion laser and a Leica 156 
DM4000B fluorescence microscopy. Pneumococcal cells were labeled with SYTO 59. 157 
The planktonic cells were sedimented by centrifugation to improve the visualization the 158 
C3b component by fluorescence microscopy. The excitation/emission maxima were 159 
around 495/519 and 622/645 nm for anti-human C3b-FITC and SYTO 59, respectively, 160 
and the magnification was ×100. Images were analyzed using the Leica software LCS. 161 
Projections through the x-y plane (individual scans at 0.5-μm intervals) and the x-z 162 
plane (images at 3-μm intervals) were obtained by CLSM. 163 
Quantification of IgG, phosphorylcholine (PCho) and PspC: Detection of IgG, 164 
Pcho or PspC on the bacterial surface of biofilms and planktonic cultures was 165 
determined by flow cytometry. Briefly, the experimental conditions of the assay were 166 
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the same than explained above except that bacterial strains were incubated during 20 167 
minutes at 37°C with 50% human serum as a source of IgG, or during 1 h at 37°C with 168 
antibodies TEPC-15 (monoclonal antibody to PCho, Sigma-Aldrich) diluted 1/25 or 169 
rabbit polyclonal antibody to PspC diluted 1/300 (a kind gift from Prof Sven 170 
Hammerschmidt, University of Greifswald, Germany). The secondary antibodies used 171 
were rabbit anti-mouse FITC (Serotec) or goat anti-rabbit FITC (Serotec) for the 172 
detection of PCho or PspC respectively. Detection of IgG by flow cytometry was 173 
measured after incubation for 20 minutes on ice with a Phycoerithryn- (PE) -conjugated 174 
donkey anti-human IgG antibody (Jackson Immunoresearch). All secondary antibodies 175 
were diluted 1/200 in PBS-Tween 20 (0.1%) and incubated for 30 minutes on ice. 176 
Phagocytosis of S. pneumoniae biofilms and planktonic cultures. Experiments 177 
investigating human neutrophil phagocytosis were performed by a flow cytometry assay 178 
using HL-60 cells (CCL-240; ATCC) differentiated to granulocytes (11, 23). The assay 179 
included the fluorescent pneumococcal P040 strain grown as biofilm or planktonic 180 
culture in CpH8 medium containing 1% maltose and 1 μg ml–1 tetracycline (19). 181 
Briefly, 96-well plates containing 1 × 106 CFU per well were infected in triplicate at a 182 
ratio of 10 bacteria:1 cell with 20 µl of a suspension of the pneumococcal P040 strain 183 
previously opsonized for 20 minutes with HBSS, heat inactivated serum (HIS) or the 184 
human serum and the mixture containing cells was incubated for 30 minutes at 37°C 185 
with shaking (150 rpm). A minimum of 6,000 cells were analyzed using a Cytomics 186 
FC500 Beckman Coulter flow cytometer equipped with a 488 nm Ar-ion laser. The 187 
presence of complement receptors on HL-60 granulocytes has been previously 188 
documented and therefore expression of CD11b (iC3b receptor and CR3 α-chain), a 189 
marker of granulocytic differentiation, was measured prior to phagocytic assays to 190 
confirm the presence of the receptor (24). Results were expressed as a FI (see above) 191 
defined as the proportion of positive cells for fluorescent bacteria multiplied by the 192 
geometric mean of fluorescence intensity which correlates with the amount of bacteria 193 
phagocytosed per cell (11, 23).  194 
8 
 
Statistical analysis. Data are representative of results obtained from repeated 195 
independent experiments, and each data point represents the mean and standard 196 
deviations (SD) for 3 to 5 replicates. Statistical analysis was performed by using two-197 
tailed Student´s t test (for two groups). GraphPad InStat version 3.0 (GraphPad 198 
Software, San Diego, CA) was used for statistical analysis. 199 
RESULTS 200 
C3b deposition on S. pneumoniae growing as biofilms or planktonic cultures. The 201 
deposition of the complement component C3b on the surface of S. pneumoniae was 202 
investigated by a flow cytometry assay using bacteria grown either as biofilms or as 203 
planktonic cultures. Since non-encapsulated pneumococci show a higher capacity to 204 
form in vitro biofilms than encapsulated isolates (reviewed in reference (6)) and to 205 
prevent any possible hindrance of the capsular polysaccharide on complement activity 206 
(12), the non-encapsulated pneumococcal R6 strain was used. In addition, to avoid 207 
possible bias in complement interaction with S. pneumoniae between the two modes of 208 
bacterial growth, biofilm disaggregation was performed before opsonization with 209 
human serum. The morphologies of S. pneumoniae cells from planktonic cultures or 210 
from disaggregated biofilms (mainly, diplococci) were indistinguishable by phase 211 
contrast microscopy confirming that disaggregation does not induce morphological 212 
changes that could affect complement interaction in further assays (not shown). 213 
Recognition of S. pneumoniae by the key complement component C3b was explored by 214 
flow cytometry using a pneumococcal strain without capsule (Figs. 1A and B) and an 215 
encapsulated clinical isolate of serotype 19A (Figs. 1C and D). C3b deposition on 216 
pneumococcal biofilms was markedly impaired in comparison to planktonic cultures 217 
suggesting that biofilm formation in S. pneumoniae is a mechanism used by the 218 
bacterium to avoid the recognition by this key complement component (Fig. 1). C3b 219 
binding was further investigated on planktonic cultures and intact biofilms of the R6 220 
strain using fluorescence microscopy and CLSM, respectively (Fig. 2). C3b bound on 221 
the bacterial surface was detected by using FITC-conjugated polyclonal goat anti-222 
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human C3b antibody (green fluorescence), whereas the pneumococcal cells were 223 
stained with SYTO 59 (red fluorescence). The entire bacterial surface of the planktonic 224 
culture was coated by C3b (Figs. 2A and B), whereas only small patches of the 225 
pneumococcal biofilm appear to contain C3b (Figs. 2C and D). This confirmed that 226 
when S. pneumoniae cells form biofilms a notable reduction of the opsonization process 227 
by C3b occurs.  228 
Reduced activation of the classical complement pathway by pneumococcal 229 
biofilms. As the classical pathway is essential for complement activation against S. 230 
pneumoniae (see above), deposition of its first component, C1q, on the R6 strain was 231 
investigated by flow cytometry. C1q deposition was significantly reduced on the surface 232 
of pneumococcal biofilms compared to planktonic cultures (Figs. 3A and B), indicating 233 
that pneumococcal biofilms hinder the activation of the classical pathway. Since 234 
recognition of S. pneumoniae by the pentraxin CRP (an acute phase protein) increases 235 
the deposition of C1q on the pneumococcal surface activating therefore the classical 236 
pathway (12) we tested whether the reduced C1q level on the surface of pneumococcal 237 
biofilms was somewhat mediated by an impaired binding by human CRP on biofilms. 238 
Actually, binding to human CRP was strongly reduced on the surface of S. pneumoniae 239 
R6 biofilms in comparison to planktonic cultures (Figs. 3C and D). These results taken 240 
together demonstrate that pneumococcal biofilms enhance the resistance of S. 241 
pneumoniae to complement immunity by diminishing the classical pathway activation. 242 
Additional experiments confirmed that the impaired recognition of S. pneumoniae 243 
biofilms by C1q and CRP was not related to differences in binding to IgG (Figs. 3E and 244 
F) or variations in the amount of the PCho epitope on the bacterial surface (Figs. 3G and 245 
H). 246 
Recruitment of human complement regulators. Interaction of pneumococcal 247 
cultures grown as biofilms or planktonic cultures with the major fluid-phase regulators 248 
of either the classical/lectin (C4BP) or alternative (FH) complement cascades was 249 
investigated by flow cytometry (Fig. 4). Deposition of C4BP was very similar in 250 
planktonic and biofilm cultures indicating that interaction with the main down-regulator 251 
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of the classical pathway is not affected by biofilm formation (Figs. 4A and B). In 252 
contrast, recruitment of FH was significantly enhanced on pneumococcal biofilms 253 
compared to planktonic cultures (Figs. 4C and D), which suggested that the impairment 254 
of the alternative pathway in pneumococcal biofilms is mediated by an increased 255 
binding to FH, the down-regulator of the alternative cascade.  256 
PspC is involved in the enhanced resistance of pneumococcal biofilms to 257 
complement-mediated immunity. It has been documented that the pneumococcal 258 
surface protein PspC (also designated CbpA) is able to bind FH (25-27). To explore the 259 
possible involvement of PspC in the increased recruitment of FH on pneumococcal 260 
biofilms, an isogenic pspC mutant of the R6 strain (P064 strain) was employed. Indeed, 261 
loss of PspC expression in P064 cells growing as biofilms caused a decrease on FH 262 
binding to levels similar to those shown by planktonic cultures of the same strain (Figs. 263 
4E, F, and G). C3b deposition assays using biofilms of the wild-type and pspC deficient 264 
strain were performed demonstrating that the increased recruitment of FH mediated by 265 
PspC confers an advantage to S. pneumoniae growing as biofilms to avoid the 266 
recognition by C3b (Figs. 5A and B). However, in the absence of PspC in both biofilms 267 
and planktonic cultures, a similar C3b deposition pattern was found confirming that this 268 
protein is clearly involved in the enhanced resistance of pneumococcal biofilms to the 269 
complement system (Figs. 5C and D). To explore the possibility that S. pneumoniae 270 
growing as biofilms might display greater levels of PspC to avoid complement mediated 271 
immunity, detection of the PspC exposed on the bacterial surface was analyzed in 272 
pneumococcal biofilms and planktonic cultures (Figs. 5E and F). Our results showed 273 
increased levels of PspC on the surface of the biofilm confirming that S. pneumoniae 274 
adopting a sessile life divert the amplification of the alternative pathway and 275 
consequently the deposition of C3b by inducing higher levels of PspC on the bacterial 276 
envelope.  277 
Phagocytosis by neutrophils is impaired in S. pneumoniae biofilms. Activation of 278 
complement immunity is a very efficient mechanism of the host immune response 279 
involved in phagocytosis of pneumococci and other encapsulated bacteria. The 280 
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susceptibility of pneumococcal biofilms to the opsonophagocytosis mediated by human 281 
neutrophils was investigated by flow cytometry using strain P040. Uptake of S. 282 
pneumoniae grown as a biofilm was markedly impaired in comparison to the planktonic 283 
culture demonstrating that the sessile growth of S. pneumoniae represents a benefit to 284 
the microorganism by avoiding very efficiently the phagocytosis mediated by human 285 
neutrophils (Fig. 6). However, in the absence of complement, (HBSS or heat inactivated 286 
serum) phagocytosis levels were drastically reduced in comparison to bacteria 287 
opsonized with serum confirming that the increased resistance to phagocytosis by 288 
pneumococcal biofilms is complement dependent (Fig. 6). Overall, these findings 289 
mirror the results obtained above regarding the interaction with different components of 290 
the complement immune response and strongly suggest that the reduced complement 291 
activation on the surface of pneumococcal biofilms confers the bacterium an enhanced 292 
resistance to be phagocytosed by professional phagocytes.  293 
DISCUSSION 294 
Bacterial biofilms are widely accepted as a frequent cause of chronic persistent 295 
infections (5). The ability of respiratory pathogens to persist in the nasopharynx and 296 
disseminate throughout the host under certain favorable circumstances, is associated 297 
with their biofilm-forming capacity on the mucosal epithelium (7). Nasopharyngeal 298 
colonization provides a stable environment to S. pneumoniae from which it can spread 299 
to other hosts and/or give rise to an infection (28). Compared to their planktonic 300 
counterparts, bacteria living as biofilms appear to have developed an evolutionary 301 
advantage because they are less sensitive to antibiotics, which complicates the 302 
effectiveness of the antimicrobial therapy (7, 29). Two main questions that remain 303 
unanswered to date is how the host defense immune system reacts to S. pneumoniae 304 
biofilms and whether or not pneumococcal biofilms can be efficiently recognized by 305 
professional phagocytes. One of the major immunological mechanisms against 306 
microbial pathogens is complement-mediated immunity that consists of a complex 307 
network of circulating and cell surface-bound proteins that play an essential role in host 308 
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defense (8, 9). In this sense, it has been shown that biofilm formation by Mycoplasma 309 
pulmonis protects from the lytic effects of complement immunity (16) whereas 310 
Staphylococcus epidermidis growing as biofilms have developed the possibility of 311 
avoiding neutrophil killing by preventing C3b opsonization (30). In this study, we have 312 
investigated the interaction of S. pneumoniae with the complement system exploring the 313 
activation and regulation of complement immunity on biofilm and planktonic bacteria. 314 
Our results indicate that pneumococcal cells within biofilms are much more effective in 315 
diverting C3b deposition on the bacterial surface than planktonic bacteria. This is 316 
relevant from the immunological perspective because C3b is essential for both the 317 
innate and adaptive immunity against pyogenic bacteria such as S. pneumoniae (8, 10, 318 
11).  319 
To unravel the mechanism behind the impaired C3b deposition on pneumococcal 320 
biofilms, the classical pathway activation was investigated, as this cascade is essential 321 
for complement immunity against pneumococcus (10, 11). Pneumococcal biofilms have 322 
been identified in children with acute otitis media (2) and therefore, the impaired 323 
classical pathway activation on S. pneumoniae biofilms may have functional 324 
consequences, as C1q protects not only from pneumococcal pneumonia and sepsis (10) 325 
but also from acute otitis media and invasive disease by avoiding the dissemination of S. 326 
pneumoniae from the middle ear to the systemic circulation (31). Our results 327 
demonstrate that biofilm formation confer to S. pneumoniae an enhanced ability to 328 
circumvent the early activation of this pathway by a C1q-dependent mechanism, which 329 
is consistent with previous results reported with Acinetobacter baumannii (17).  330 
The classical pathway can also be activated on S. pneumoniae by acute phase proteins 331 
such as CRP (22). CRP is the main acute phase reactant in humans and indeed, CRP 332 
levels markedly increase after pneumococcal infection, which confirms the importance 333 
of this molecule for S. pneumoniae recognition (32). Our findings show that biofilm 334 
formation in S. pneumoniae is associated with a reduced recognition by human CRP. 335 
This is in agreement with that previously reported for coagulase-negative 336 
staphylococcal biofilms (33) but contrasts with the claim that an enhanced production of 337 
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choline phosphate, which is known to bind CRP, occurs during biofilm development 338 
(34). Our results suggest that the impaired activation of the classical pathway on the 339 
surface of pneumococcal biofilms is not due to differences in phosphorylcholine or 340 
variation in the binding to IgG. There are evidences confirming that CRP binds the 341 
complement component C1q through its globular head region activating therefore the 342 
classical pathway (35, 36). In this sense, our results indicate that S. pneumoniae 343 
growing as biofilms have the ability to avoid the direct interaction of C1q with the 344 
pneumococcal surface as a recent study has demonstrated that C1q can directly 345 
recognize S. pneumoniae in the absence of any mediator (37).  346 
Recruitment of regulators for complement activation is a common strategy used by 347 
different microorganisms for complement evasion (38). The PspC protein of S. 348 
pneumoniae binds FH reducing the activation of the alternative complement pathway 349 
(27). Our results demonstrated that recruitment of FH was markedly enhanced by 350 
pneumococcal biofilms compared to their planktonic counterparts in a PspC-dependent 351 
manner and are in accordance with a recent report showing that pneumococci increase 352 
the production of PspC when grown under biofilm forming conditions (34). Our 353 
findings demonstrate that the increased presence of PspC on the surface of 354 
pneumococcal biofilms have functional consequences in terms of subversion of 355 
complement mediated immunity by reducing the activation of the alternative pathway 356 
through a FH dependent mechanism. In contrast, a significant difference in the 357 
deposition of C4BP onto biofilms as compared to planktonic pneumococcal cultures 358 
was not apparent. A variety of bacteria interact with C4BP to facilitate immune evasion 359 
(reviewed in reference (39). It has been reported that the binding of C4BP to S. 360 
pneumoniae is PspC allele-dependent, being the R6/D39 allele a weak binder (40). 361 
More recently, however, it has been reported that the pneumococcal glycolytic enzyme 362 
enolase, a moonlighting surface protein (41), recruited C4BP, but not FH (39). Previous 363 
proteomic analyses using procedures different to that employed in this study to grow 364 
pneumococcal biofilms have show either a transient increase (42) or a marked inhibition 365 
in enolase biosynthesis (43). This discrepancy has been attributed to the different strains 366 
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used, the different age of the biofilms examined, and/or to differences in the criteria 367 
used for protein identification in both studies. Assuming that significant changes on the 368 
binding of C4BP to biofilm- and planktonic-grown cells have not been found, we 369 
propose that no major alterations on enolase production take place under our 370 
experimental conditions. Overall, our study shows for the first time that S. pneumoniae 371 
biofilms avoid complement immunity by targeting both the classical and alternative 372 
pathway using a complex mechanism of impaired activation and increased down-373 
regulation, respectively. 374 
Clearance of S. pneumoniae by professional phagocytes requires an efficient 375 
opsonization of the bacterium by the complement system (8). Biofilm formation has 376 
been suggested to be a pivotal event in the pathogenesis process of numerous infectious 377 
diseases (5) and is consistent with our findings as long as the reduced complement 378 
activation on S. pneumoniae biofilms confers a significant benefit to the virulence of the 379 
microorganism. Reduced phagocytosis has been previously documented for other 380 
bacterial species growing as biofilms, confirming that sessile communities of certain 381 
microbial pathogens are more resistant to opsonic killing by host phagocytes than 382 
planktonic cells (15, 44, 45). In the case of S. pneumoniae, biofilm matrices consist of a 383 
mixture of extracellular polymeric substances composed of extracellular DNA, proteins 384 
and polysaccharides that are synthesized in large part by the pneumococcal strains 385 
producing the biofilm. The relevance of these matrices is because they are responsible 386 
for the cohesion and three-dimensional architecture of biofilms (46). In terms of host-387 
pathogen interaction, the presence of an extracellular matrix during biofilm formation 388 
improves the virulence of S. pneumoniae (47). The results of our study fully confirm 389 
that opsonophagocytosis of pneumococcal biofilms was significantly impaired in 390 
comparison to the planktonic cultures and demonstrate that pneumococcal biofilms have 391 
developed an increased resistance to the phagocytosis process mediated by human 392 
neutrophils. Taken together, our findings suggest that biofilm formation may constitute 393 
an evolutionary advantage in certain phases of the pneumococcal pathogenic process, 394 
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such as nasopharyngeal colonization or during the early steps of microbial attachment 395 
for invasion, by avoiding the host immune system. 396 
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FIGURE LEGENDS 559 
 560 
FIG 1 C3b deposition on the surface of the R6 strain grown as planktonic culture (PK) 561 
or as a biofilm (BF) (A). Results are expressed as a relative % FI relative to the results 562 
for PK culture. (B) Example of a flow cytometry histogram for C3b deposition. A 563 
control (CT PBS) incubated with PBS instead of human serum is also shown. (C) C3b 564 
deposition on the surface of the encapsulated clinical isolate of serotype 19A grown as 565 
planktonic culture (PK) or as a biofilm (BF) (D). Results are expressed as a relative % 566 
FI relative to the results for PK culture. Error bars represent standard deviations and 567 
asterisks mark results that are statistically significant compared to bacteria growing as 568 
PK (two-tailed Student’s t test, *P <0.001). 569 
 570 
FIG 2 C3b deposition on the surface of the R6 strain grown as planktonic cultures or as 571 
biofilms. A planktonic culture of R6 strain was stained with SYTO 59 (A, red) and C3b 572 
deposition on the surface of the planktonic culture of the R6 strain was visualized using 573 
a FITC-conjugated polyclonal goat anti-human C3b antibody (B, green). To enhance the 574 
quality of the picture, the culture was centrifuged and gently resuspended in PBS after 575 
labeling and prior to examination at the fluorescence microscope (C–E) Localization by 576 
CLSM of the human C3b component on the surface of biofilm-grown R6 strain. A 577 
biofilm of the S. pneumoniae strain R6 was stained with a combination of SYTO 59 (C, 578 
red) and a FITC-conjugated polyclonal goat anti-human C3b antibody (D, green). Image 579 
(E) is a merger of the two channels. Scale bars = 25 μm. 580 
 581 
FIG 3 Deposition of C1q, CRP and IgG on the surface of the R6 strain grown as 582 
planktonic culture (PK) or as biofilm (BF) and detection of PCho in PK and BF 583 
cultures. (A, C and E) Deposition of C1q, CRP and IgG respectively. (B, D and F) 584 
Examples of flow cytometry histograms for the binding of C1q, CRP and IgG 585 
respectively. (G) Detection of PCho on the surface of the R6 strain grown as planktonic 586 
culture (PK) or as biofilm (BF). (H) Example of a flow cytometry histogram for the 587 
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detection of PCho. Results are expressed as a relative % FI relative to the results for PK 588 
culture. Controls incubated with PBS instead of human serum (CT PBS) are also shown. 589 
Error bars represent standard deviations and asterisks mark results that are statistically 590 
significant compared to bacteria growing as PK (two-tailed Student’s t test, *P <0.001). 591 
 592 
FIG 4 Recruitment of down-regulators of the complement system by the R6 strain 593 
grown as planktonic culture (PK) or as a biofilm (BF). (A) Recruitment of C4BP by the 594 
R6 strain as PK (open bar) or as BF (grey bar). (B) Example of a flow cytometry 595 
histogram for the deposition of C4BP on R6 strain. (C) Recruitment of FH by the R6 596 
strain as PK (open bar) or as BF (grey bar). (D) Example of a flow cytometry histogram 597 
for the deposition of FH on R6 strain. (E-F) Recruitment of FH by the P064 (R6 pspC) 598 
strain as PK (open bar) or as BF (grey bar). (G) Example of a flow cytometry histogram 599 
for the recruitment of FH on P064 strain. Results are expressed as a relative % FI 600 
relative to the results for PK culture except in panel F, where results indicate the mean 601 
fluorescence intensity. Error bars represent standard deviations and asterisks mark 602 
results that are statistically significant compared to bacteria growing as PK (two-tailed 603 
Student’s t test, *P <0.001). Controls incubated with PBS instead of human serum are 604 
also shown (CT PBS). 605 
 606 
FIG 5 Effect of PspC in complement evasion and levels of PspC in planktonic culture 607 
(PK) and biofilm (BF). (A) Deposition of C3b on the surface of the R6 strain or its 608 
isogenic pspC mutant strain growing both as biofilms. (B) Example of a flow cytometry 609 
histogram for the deposition of C3b on R6 and P064 (R6 pspC) strains as BF. (C) 610 
Deposition of C3b on the surface of the pspC strain growing as PK or BF. (D) Example 611 
of a flow cytometry histogram for the deposition of C3b on P064 (R6 pspC). (E) 612 
Detection of PspC on the bacterial surface of R6 strain growing as PK or as BF. (F) 613 
Example of a flow cytometry histogram for the detection of PspC on R6 growing as PK 614 
or as BF. Error bars represent standard deviations and asterisks mark results that are 615 
statistically significant compared to bacteria growing as PK (two-tailed Student’s t test, 616 
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*P <0.001). Controls incubated with PBS instead of human serum are also shown (CT 617 
PBS). 618 
 619 
FIG 6 Opsonophagocytosis of the R6-GFP strain grown as planktonic culture (PK) or 620 
as a biofilm (BF). (A) Opsonophagocytosis of the P040 strain as PK (open bar) or as BF 621 
(grey bar). Negative controls of bacteria incubated with HBSS or heat inactivated serum 622 
(HIS) instead of human serum are also shown. (B) Example of a flow cytometry 623 
histogram for the opsonophagocytosis. Results are expressed as a relative % FI relative 624 
to the results for PK culture. Error bars represent standard deviations and asterisks mark 625 
results that are statistically significant compared to bacteria growing as PK (two-tailed 626 
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